EP
AQST icon

Essential Partners’s Aquestive Therapeutics AQST Stock Holding History

Essential Partners’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$218 Hold
47
– – ﹤0.01% 2580
2026
Q2 		$196 Hold
47
– – ﹤0.01% 2640
2026
Q1 		$195 Hold
47
– – ﹤0.01% 2614
2025
Q4 		$304 Hold
47
– – ﹤0.01% 2337
2025
Q3 		$263 Hold
47
– – ﹤0.01% 2350
2025
Q2 		$156 Buy
+47
New +$135 ﹤0.01% 1997

Other funds holding AQST

Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
SMAM
Sugar Maple Asset Management Sister Bay, Wisconsin $175M AUM 16.33% 1-Year Est. Return
PM
Penbrook Management New York $169M AUM 32.52% 1-Year Est. Return
ACA
Adirondack Capital Advisors Syracuse, New York $194M AUM 14.02% 1-Year Est. Return
CCM
Cox Capital Management Andover, Massachusetts $179M AUM 28.94% 1-Year Est. Return
Lineweaver Wealth Advisors
Lineweaver Wealth Advisors Valley View, Ohio $863M AUM 14.27% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
Newbridge Financial Services Group
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Essential Partners's AQST Position: Q3 2026 in Review

Essential Partners held its Aquestive Therapeutics (AQST) position steady in Q3 2026 at 47 shares worth $218. The position accounts for ﹤0.01% of the portfolio, ranked #2580.

Essential Partners first reported a position in AQST in Q2 2025 and has held it in 6 quarters since. The position peaked at $304 in Q4 2025. 13 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

  • Essential Partners held 47 shares of Aquestive Therapeutics worth $218 as of Q3 2026.
  • Essential Partners left its Aquestive Therapeutics share count unchanged in Q3 2026.
  • Aquestive Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2580 holding.
  • Essential Partners first reported a position in Aquestive Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's Aquestive Therapeutics position peaked at $304 in Q4 2025.
  • 13 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.